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Abstract. The functional significance of the actin-bind- 
ing domain of dystrophin, the protein lacking in pa- 
tients with Duchenne muscular dystrophy, has re- 
mained elusive. Patients with deletions of this domain 
(domain I) typically express low levels of the truncated 
protein. Whether the moderate to severe phenotypes 
associated with such deletions result from loss of an es- 
sential function, or from reduced levels of a functional 
protein, is unclear. To address this question, we have 
generated transgenic mice that express wild-type levels 
of a dystrophin deleted for the majority of the actin- 
binding domain. The transgene derived protein lacks 
amino acids 45-273, removing 2 of 3 in vitro identified 
actin interacting sites and part of hinge 1. Examination 
of the effect of this deletion in mice lacking wild-type 
dystrophin (mdx) suggests that a functional domain I is 
not essential for prevention of a dystrophic phenotype. 
However, in contrast to deletions in the central rod do- 
main and to full-length dystrophin, both of which are 
functional at only 20% of wild-type levels, proteins with 
a deletion in domain I must be expressed at high levels 
to prevent a severe dystrophy. These results are also in 
contrast to the severe dystrophy resulting from trunca- 
tion of the COOH-terminal domain that links dystro- 
phin to the extracellular matrix. The mild phenotype 
observed in mice with domain I-deletions indicates that 
an intact actin-binding domain is not essential, although 
it does contribute to an important function of dystro- 
phin. These studies also suggest the link between dys- 
trophin and the subsarcolemmal cytoskeleton involves 
more than a simple attachment of domain I to actin fila- 
ments. 
UCHENNE muscular dystrophy is a severe X-linked 
lethal myopathy caused by mutations in the dys- 
trophin gene (Koenig et al., 1987). Patients with 
mutations in this gene display quantitative and/or qualita- 
tive deficiencies in expression of the protein dystrophin. 
Phenotypically, this  defect results  in  progressive muscle 
degeneration initially manifested in limb skeletal muscles, 
while patient death generally occurs from respiratory or 
cardiac failure (Emery, 1993).  The milder Becker muscu- 
lar dystrophy (BMD) 1 is an allelic disease characterized by 
a later age of onset and a slower progression of muscle de- 
generation  (Bushby,  1992).  Dystrophin is  also  absent in 
the rndx mouse, an animal model for DMD (Bulfield et al., 
1984). 
Based  on  structural  similarities  with  the  cytoskeletal 
proteins, a-actinin and spectrin, the dystrophin molecule is 
thought to be composed of four distinct domains: an NHe- 
terminal actin-binding domain (domain I), 24 c~-helical re- 
peats that form a coiled-coil central rod domain, and two 
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globular COOH-terminal domains, the first containing a 
cysteine-rich region, followed by an alternatively spliced 
region (Fig.  1 a; for reviews see Ahn and Kunkel, 1993; 
Amalfitano et al., 1996). NH2-terminal fragments of dys- 
trophin bind actin in vitro and localize to the sarcolemma 
of muscle fibers (Hoffman et al.,  1991; Way et al.,  1992; 
t-Ielliwell  et al., 1992; Corrado et al., 1994; Dunckley et al., 
1994; Jarrett and Foster, 1995). The COOH-terminal do- 
main binds to a transmembrane glycoprotein complex that 
attaches to laminin in the extracellular matrix (Ervasti and 
Campbell,  1991; Dickson et al., 1992; Ervasti and Camp- 
bell, 1993). These observations have led to the hypothesis 
that dystrophin forms a structural link between the sarco- 
plasmic  cytoskeleton  and  the  extracellular  matrix  that 
helps to protect the sarcolemma from damage during con- 
traction. 
Ultrastructurally, dystrophin is localized to the cytoplas- 
mic surface of the sarcolemma (Zubrzycka-Gaarn et al., 
1988).  Dystrophin  is  concentrated  at  distinct  regions 
termed costameres which form transverse associations be- 
tween the sarcolemma and the contractile elements of the 
myofiber, suggesting that dystrophin may interact with a 
number  of other  cytoskeletal proteins  (Minnetti  et  al., 
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1992). Dystrophin associates with aciculin in cultured mus- 
cle cells and binds talin in vitro (Belkin and Burridge 1995; 
Senter et al., 1993).  Several groups have observed dystro- 
phin at internal regions of the myofiber. In particular, dys- 
trophin has been localized within the skeletal muscle sar- 
comere as a pair of thicker lines overlying the I band and 
at a region overlying the M lines (Masuda et al., 1992; Por- 
ter et al.,  1992).  Taken together, these observations sug- 
gest that  dystrophin plays a  complex role in the  mature 
myofiber. However, the specific function(s) of dystrophin 
in different cellular compartments is not known. 
Correlation of mutations with severity of phenotype has 
allowed inferences as to the functional importance of cer- 
tain domains  of dystrophin  (Amalfitano et al.,  1996).  In 
general, mutations that disrupt the normal reading frame 
lead  to  more  severe  symptoms  associated  with  DMD, 
whereas mutations  that cause in-frame deletions  lead  to 
the  less severe BMD  (Monaco et al.,  1988).  However, a 
number of exceptions to this rule have been observed, the 
majority of which involve deletions in domain I. One class 
of exceptions involving domain I are patients with a dele- 
tion of exons 3-7. This deletion is an mRNA frame-shifting 
mutation yet these patients display a range of phenotypes 
including  BMD  (Malhotra  et  al.,  1988;  Baumbach  et  al., 
1989; Koenig et al., 1989; Winnard et al., 1993). These pa- 
tients frequently express low levels of a dystrophin gener- 
ated either by exon skipping or by translational initiation 
at an AUG in exon 8  (Chelly et al.,  1990;  Thanh  et al., 
1993; Winnard et al., 1995). The fact that some patients ex- 
pressing a  dystrophin lacking exons 1-7  display a Becker 
phenotype suggests that  the actin-binding  domain  is not 
critical  (Winnard  et  al.,  1995).  Other  exceptions  to  the 
frame-shift rule have been observed in patients with small 
in-frame deletions in domain I. These patients display great 
phenotypic variability, often involving a more severe phe- 
notype than expected and a  faster rate of progression of 
muscle breakdown (Koenig et al., 1989; Beggs et al., 1991; 
Comi et al., 1994; Muntoni et al., 1994).  It has also been re- 
ported that dystrophin proteins deleted for portions of do- 
main I are consistently found at levels well below those in 
normal control muscle (Beggs et al., 1991; Winnard et al., 
1993; Muntoni et al., 1994). 
The structural model suggests that dystrophin binding to 
actin at the NH2 terminus and to the dystrophin-glycopro- 
tein complex (DGC) at the COOH terminus forms a  di- 
rect link  between  the  intracellular  cytoskeleton  and  the 
extracellular  matrix  that  is  critical  for  maintaining  the 
structural  integrity of the  sarcolemma (Campbell, 1995). 
In  concordance  with  this  model,  mutations  of  various 
DGC members, laminin,  or the COOH-terminal domain 
of  dystrophin  all  lead  to  a  severe  muscular  dystrophy 
(Matsumura et al., 1993; Roberds et al., 1994; Tome et al., 
1994; Noguchi et al., 1995; B6nnemann et al., 1995; Lim et al., 
1995).  In contrast, the variable phenotypes observed in pa- 
tients with NH2-terminal deletions of dystrophin has made 
correlations of structure and function in this domain less 
clear. Specifically, it is unclear whether the phenotypes as- 
sociated with deletions in domain I  are due to mutations 
that cause a loss of cytoskeletal attachment, or from desta- 
bilization of the protein resulting in low levels of a func- 
tional molecule. We addressed this question by monitoring 
the  effects of a  deletion  in  domain  I  in  transgenic mdx 
mice.  By  overexpressing an  internally  truncated  dystro- 
phin, we were able to generate higher levels of dystrophin 
than are found in patients with similar mutations. Our re- 
sults indicate that the actin-binding domain I is not essen- 
tial for dystrophin function, and that normal levels of dys- 
trophin containing a deletion in this domain lead to a very 
mild dystrophic phenotype. 
Materials and Methods 
Construction of  Plasmids  for Embryo Microinjection 
Plasmid pAabdl  was constructed from pCAA, a  plasmid containing the 
-3,300-bp mouse muscle creatine kinase (MCK) gene promoter plus en- 
hancer (Johnson et al., 1989),  the 13,815-bp murine dystrophin cDNA, 
and the SV40 polyadenylation signal (Phelps et al., 1995). The extreme 5' 
end of the dystrophin cDNA was excised as a 1.4-kb NotI-SpeI fragment 
and ligated into pBluescript If SK- (Stratagene, La Jolla, CA) from which 
the PstI site had been destroyed. A PstI-NsiI fragment that spanned bases 
355-1041 of the dystrophin cDNA (Lee at al., 1991;  Chamberlain et al., 
1991)  was excised from the latter plasmid, which was then self-ligated to 
create a  687-bp deletion. This truncated fragment was then excised as a 
NotI-Spel  fragment and religated  into  the original  NotI-SpeI  sites of 
pCAA to create a dystrophin expression vector deleted for the actin-bind- 
ing domain (Fig. 1 a). The correct construction of this clone was verified 
by restriction enzyme analysis, the polymerase chain reaction (PCR) using 
primers outside of the deletion, and DNA sequencing through the deleted 
region. Plasmid pAabd2 is similar to pAabdl except that it contains the 
SV40 VP1  intron inserted between the MCK promoter and dystrophin 
(Phelps et aL, 1995). 
Generation of Transgenic Mice 
Transgenic mice were generated by microinjection of purified pAabdl or 
pAabd2 insert into 1=2 hybrid zygotes from C57B1/6J  x  SJL/J parents as 
described (Hogan et al., 1986).  Positive transgenic mice were identified by 
PCR analysis of tail DNA using primers specific for the 3' end of the mu- 
rine dystrophin cDNA and the SV40 polyadenylation site. The presence 
of the deletion within the cDNA was verified by PCR  using a  primer 
within the MCK promoter and a  primer within the dystrophin cDNA. 
Positive Fo mice were also verified by hybridization of genomic tail DNA 
with a probe  internal to the dystrophin cDNA. Transgenic mice on the 
mdx background were produced by crossing Fo transgenic male mice with 
C57BL/lOmdx females. Transgenic F1 males were then bred with C57BL/ 
lOmdx females to produce both male and female offspring on the mdx 
background. 
Histological Analysis 
Histological 4-lxm sections were prepared from muscle tissues fixed in 4% 
paraformaldehyde and 1% glutaraldehyde, embedded in glycol methacry- 
late, and stained with hematoxylin and eosin. For central nuclei counts, 
histological sections were photographed and the percentage of centrally 
nucleated myofibers was determined by dividing the number of myofibers 
containing one or more centrally located nuclei by the total number of nu- 
cleated fibers. Myofibers with no nuclei in the plane of section were not 
counted. 
Immunofluorescent Localizations with 7-tzm 
Transverse Cross-Sections 
Skeletal muscle was removed from mice, cut into strips, and frozen slowly 
in  tissue-tek  OCT  media.  Unfixed  ~7-t~m  muscle  cryosections  were 
stained as described previously with an affinity-purified rabbit polyclonal 
antibody against a fusion protein with the last 315 amino acids of murine 
dystrophin, which was preadsorbed to eliminate cross reactivity with utro- 
phin (Cox et al., 1994). 
Immunofluorescent Localizations with Thin Sections 
Freshly dissected mouse quadriceps muscle was cut into small pieces (~1 
mm x  1 ram) and fixed in 1.2% formaldehyde/PBS for 1 h on ice. The tis- 
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at 4°C. Longitudinally oriented mounted tissue blocks were quick frozen 
in liquid nitrogen.  0.5-1.0 p,m sections were cut at  -80°C using an UI- 
tracut  E, FC4 cryomicrotome  (Riechert-Jung, Vienna).  Tissue sections 
were blocked for 2 h at 4°C with 5% normal goat serum (Jackson Immu- 
noresearch,  West Grove, PA) in PBS, incubated  overnight with primary 
antibodies, washed, and incubated  for 4 h at 4°C with either fluorescein- 
or rhodamine-conjugated  secondary antibodies. All washes were done in 
PBST (0.5  % Tween-20) and antibody dilutions were in PBS plus 1% nor- 
mal goat serum. Rhodamine-conjugated  phalloidin (Sigma Chem. Co., St. 
Louis, MO) was used at a concentration of 10 nM and anti--a-actinin as- 
cites fluid (mAb1682, Chemicon, Temecula,  CA) was diluted  1:500. Im- 
munofluorescence  was observed on a Zeiss Axioscope  equipped with a 
Canon EDS63 camera. All photography was performed with TMAX 400 
film (Eastman-Kodak,  Rochester, NY). 
normal goat serum (secondary antibodies).  Bound alkaline phosphatase:~ 
conjugated  secondary  antibodies  were visualized using NBT and B~]~  / 
(Sigma Chem. Co.). Dystrophin expression levels in transgenie mice wer~ 
estimated by comparison with extracts from control mice on multiple 
dependent blots, an example of which is shown in Fig. I b. 
Measurement of Muscle Mechanical Properties 
Small bundles of intact fibers were removed from the diaphragm muscles 
of 6-7-month old mice. Specific force (kN/m  2) was determined during. 
maximum isometric tetanic contraction in vitro at 25°C, and then normal- 
ized to total cross-sectional area. Power output (W) was determined  by is- 
ovelocity shortenings from 100% Lo to 90% Lo during maximum muscle 
activation, and was normalized  by muscle mass (McCulty and Fautkner; 
1984; Cox et al., 1993). 
Western Blot Analysis 
Total muscle protein homogenates were prepared from either quadriceps 
or diaphragm  tissues frozen in liquid nitrogen. Tissues were ground to a 
fine powder under liquid N2, suspended in homogenate buffer (1% SDS, 
5 mM EGTA, 1 mM PMSF, 1 mM benzamidine, 0.5 mg/rnl leupeptin, and 
0.2 U/ml aprotinin), vortexed briefly, and heated to 100°C for 2 rain. Insol- 
uble material  was removed by centrifugation  (5 rain, 12,000 rpm at 4°C) 
and the supernatant was stored at -80°C. Proteins separated on 2-12% 
agarose-acrylamide  composite  gradient  gels  were  transferred electro- 
phoretically onto nitrocellulose for I h at 2 mA/cm  2 using a semidry trans- 
blotter (Khyse-Anderson, 1984; Wang et al., 1989). Purified rabbit  myo- 
fibriUar proteins were  used  as  molecular  weight  standards  and  were 
stained with India ink after transfer.  Membranes were blocked in TBST 
(1% Tween-20) containing 5% wt/vol nonfat instant dry milk powder. An- 
tibodies were diluted  in TBST (primary  antibodies)  or TBST plus 0.5% 
Results 
Phenotypic Analysis of Transgenic mdx Mice 
To study the function of the actin-binding domain of dys~ 
trophin,  transgenic  mice  were  generated  that  express a 
murine dystrophin cDNA construct that is missing amino 
acids 45-273 (Fig. t a). This deletion is similar to exon 3::7 
deletions found in many patients, except it retains the first 
13  amino acids of exon 3  and extends to  the middle 0f 
exon 8, thereby maintaining an open reading frame. The 
internally truncated  protein joins  amino  acid  44  to  the 
middle of hinge 1, eliminating virtually the entire NH#ter= 
Figure  I.  Generation  of 
transgenic  mice  expressing 
dystrophin  with  an  acti-m 
binding domain deletion. (a) 
Diagram  of the vector use~ 
to  generate  the  transgenie 
mice (not to scale). The mu: 
rine  dystrophin  cDNA  con- 
taining  a  deletion  'A'  be= 
tween internal PstI and Nsit 
sites  was  regulated  by  the 
-3300  to  +7  bp  MCK  pro= 
motet/enhancer,  and  the 
SV40  poly-adenylation  site; 
either  with  or  without  the 
SV40 VP1  intron inserted in 
a  NotI  site.  Indicated  ar~ 
cDNA  sequences  that  eri: 
code  the  actin-binding  do'; 
main  I  of  dystrophinl- four 
hinge  regions,  24  spectr~lw 
like  repeats,  and  the  cys, 
teine-rich (CR)  and aitetna= 
tively  spliced  COOH,termi,- 
nal  (CT)  domains.  (b) 
Western blot analysis of total 
muscle  proteins  in  control 
(C57), dystrophin (mdx), and 
transgenic (lines 1F and 2F) 
mice.  Transgenic  muscle 
from both lines expressed an 
,'-~400-kD  protein.  Expres- 
sion of the transgene in line 
1F  was  approximately  the 
same as the dystrophin levels in control mice in both quadriceps and diaphragm. Expression of the transgene in line 2F was ,~2-3 times 
the level of dystrophin in the quadriceps muscle and approximately equal to the level of dystrophin in diaphragm muscle of control 
mice. Upper arrowhead indicates the position of the full-length 426-kD dystrophin; the lower arrowhead indicates the position of the 
400-kD truncated dystrophin. 
Corrado et al. Deletion of the Dystrophin Actin-binding Domain  875 Figure 2.  Immunofluorescence localization of dystrophin in quadriceps muscle. Dystrophin staining at the sarcolemma appears uniform 
in the quadriceps muscle of control (A) and transgenic lines Aabd-lF (C) and Aabd-2F (D). Note the absence of dystrophin labeling in 
mdx muscle (B). Bar is 50 microns. 
minal  domain of dystrophin (Koenig and Kunkel, 1990). 
Mice positive for the transgene were bred onto an mdx ge- 
netic background to generate lines expressing the trans- 
gene-encoded protein in the absence of endogenous dys- 
trophin. Transgenic mouse lines were established from 12 
Fo  animals  and  analyzed  by  immunoblot  to  determine 
which were expressing normal or above normal levels of 
the internally truncated dystrophin (data not shown). In 
contrast to other transgenic dystrophin mice we have gen- 
erated,  a  level  of  expression  significantly  greater  than 
wild-type was not obtained in any of the 12 lines express- 
ing this  construct (Cox et  al.,  1993;  Phelps  et al.,  1995). 
This lack of high level expression may be due to an inher- 
ent instability of a protein with this deletion, as has been 
suggested for human patients with similar deletions (Beggs et 
al., 1991). Based upon the Western blot analysis, two inde- 
pendent lines of transgenic mice (Aabd-lF and Aabd-2F) 
were chosen for detailed analysis. Expression of the trans- 
gene in line Aabd-lF produced ~-,80% of control dystro- 
phin levels in both quadriceps and diaphragm (Fig. 1 b and 
data not shown). Expression of the transgene in line Aabd- 
2F (which unlike the 1F transgene included a VP1 intron) 
generated ~2-3 times the control levels of dystrophin in 
quadriceps muscles and similar to control levels of dystro- 
phin in diaphragm (Fig. 1 b and data not shown). Dystro- 
phin expression in three additional lines was moderate to 
low in quadriceps and diaphragm muscles so these latter 
mice were not extensively analyzed (see below). 
We next examined both quadriceps and diaphragm mus- 
cles using antibodies that recognize the COOH terminus 
of dystrophin to determine if the internally truncated pro- 
tein was localized correctly in the mdx muscles (Cox et al., 
1994). As in control mice, the dystrophin was localized at 
the sarcolemma membrane (Figs. 2 and 3). In quadriceps 
of  both  transgenic  lines,  the  signal  was  uniform  and 
present in all fibers (Fig. 2, C and D). While line Aabd-lF 
also displayed uniform expression of dystrophin in the dia- 
phragm muscles (Fig. 3 C), line Aabd-2F diaphragm mus- 
cle contained areas of fibers displaying uniform staining 
mixed with areas displaying highly variable levels of stain- 
ing, including some regions with little or no staining.  In 
many areas a fiber-to-fiber variability was also observed in 
which  very large  diameter fibers were  intensely stained 
while nearby smaller diameter fibers displayed very low- 
level staining (Fig. 3 D). We have previously described a 
number of transgenic lines with mosaic patterns of expres- 
The Journal of Cell Biology, Volume 134, 1996  876 Figure 3.  Immunofluorescence localization of dystrophin in diaphragm muscle. Dystrophin is localized uniformly at the sarcolemma in 
control muscle (A), but is not detected in mdx muscle (B). Muscle from transgenic line Aabd-lF (C) also displays a uniform staining pat- 
tern, but the intensity of the staining is slightly lower than in control muscle. Transgenic line Aabd-2F (D) displays a more variable stain- 
ing pattern. In some regions, large diameter fibers are more intensely stained than nearby smaller diameter fibers (D). Other regions of 
the diaphragm from line Aabd-2F display areas with no staining interspersed with region of moderate staining. Bar is 50 microns. 
sion, which results from a  position effect variegation due 
to chromatin differences at the site of integration of each 
particular transgene array in a line of animals (Rafael et al., 
1994;  Phelps et al.,  1995;  Milot et al.,  1996).  Three other 
lines of mice displayed either very low expression of dys- 
trophin in diaphragm or were more mosaic than line Aabd- 
2F  (not  shown).  Highly  mosaic  dystrophin  expression 
leads to a dystrophic phenotype, even with full-length dys- 
trophin (Phelps et al., 1995), so we did not further analyze 
these latter lines of mice. 
To determine the effect of the domain [  deletion,  dia- 
phragm  and  quadriceps  muscle  sections  were  examined 
morphometrically. The absence of dystrophin in mdx mice 
leads to cycles of muscle fiber degeneration and regenera- 
tion, variable fiber diameters, and a gradual increase in fi- 
ber  necrosis  (Bulfield  et  al.,  1984;  Torres  and  Duchen, 
1987;  Stedman  et  al.,  1991).  These  muscles  also  display 
variable amounts of infiltration by mononuclear cells, in- 
dicative of an inflammatory response,  accompanied by a 
progressive replacement of the  muscle with adipose and 
connective tissue (fibrosis). Histological analysis indicated 
that  quadriceps  muscle in  the  transgenic mice was much 
less affected than in mdx mice (Fig. 4). Few necrotic fibers 
were observed and little fibrosis was evident, although  a 
variation  in  fiber  size  was  apparent.  The  percentage  of 
muscle fibers with centrally located nuclei is indicative of 
previous  cycles  of degeneration/regeneration,  and  is  in- 
versely correlated with the overall ability of a  dystrophin 
molecule to protect muscle from necrosis  and  regenera- 
tion (Phelps et al., 1995).  The percentage of centrally nu- 
cleated fibers observed in quadriceps muscles of 3-4-month- 
old mice was ,'~8% for transgenic mdx  line  Aabd-lF and 
,--~7%  for  line  Aabd-2F  compared  with  <1%  for  age- 
matched C57BL/10 and ~80%  for mdx  (Table I). These 
data  indicate  that  in  quadriceps  muscles,  the  internally 
truncated  protein  is  able  to  prevent  the  appearance  of 
most dystrophic symptoms. In mdx  mice, the  diaphragm 
muscles  show  more  degeneration  and  necrosis  of fibers 
(Stedman  et  al.,  1991)  and  a  greater  loss  of  force  and 
power (Cox et al., 1993)  than limb muscles do and conse- 
quently more closely resemble the phenotype observed in 
DMD patients. In the Aabd-lF line morphological analysis 
of the diaphragm muscle revealed a relatively normal ap- 
pearance,  with  few detectable  necrotic fibers  (Fig.  5  C). 
Corrado et aL Deletion of the Dystrophin Actin-binding Domain  877 Figure 4.  Histological  analysis of quadriceps  muscle. Haematoxylin and eosin staining  of control C57BL/10 (A) and transgenic  rndx 
muscle of lines Aabd-lF (C) and Aabd-2F (D) reveal little or no fibrotic infiltration  of the muscles compared with the dystrophic pathol- 
ogy observed in rndx mice (B). Few necrotic fibers were observed in control or transgenic  mice, and little inflammation was apparent; 
however, a variation in fiber size in the transgenic muscle was noted as was an increased number of fibers with centrally located nuclei. 
Bar is 50 microns. 
The percentage of diaphragm muscle fibers with centrally 
located  nuclei  averaged  ~11%  for  line  Aabd-lF,  com- 
pared  with  <0.2%  for  age-matched  C57BL/10  control 
mice and ,-~55% for mdx mice (Table I). These results sug- 
gest that  in  diaphragm muscle, as in the  quadriceps,  the 
deleted protein is able to prevent most of the dystrophic 
symptoms normally present in mdx mice. In contrast, the 
diaphragm  muscle  of line  Aabd-2F  had  a  variable mor- 
Table I. Centrally Nucleated Fibers in Muscles of Mice 
Percentage of centrally 
nucleated fibers 
Line  Animal*  Diaphragm  Quadriceps 
C57  0.2  0.7 
IF  3647  10.8  5.3 
IF  4436  11.8  13.6 
2F  4045  ND  10.0 
2F  4805  ND  4.5 
mdx  54.8  88.7 
* All mice tested were 3-4 months of age. ND, not determined. 
phology from one region  of the  muscle to  another.  This 
line of mice displayed a very mosaic pattern of dystrophin 
expression, and, as a result, some regions of muscle looked 
very healthy (Fig. 5 D) while others looked similar to mdx 
muscle (Fig. 5 E). Three other lines of mice with low or ex- 
tremely  mosaic  dystrophin  expression  displayed  a  dia- 
phragrn muscle morphology similar to mdx mice (not shown). 
Functional Analysis of the Truncated Dystrophin 
The diaphragm muscles from mdx mice display a  signifi- 
cant functional deficit, manifested by dramatic reductions in 
the generation of both force and power (Cox et al., 1993; 
Rafael et al., 1994; Phelps et al., 1995). To maximize poten- 
tial differences between the transgenic and mdx mice, me- 
chanical properties of muscles were measured in mice 6-7 
months of age. By this age diaphragm muscles from mdx 
mice display a 57% reduction in specific force compared with 
age  matched  control  mice  (C57BL/10).  In  contrast,  dia- 
phragm muscles from transgenic Aabd-lF mice displayed 
only a 27% reduction in specific force (Table II). Similarly, 
the normalized power generated by diaphragm muscles of 
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Specific force  ~:  Normalized power* 
Line*  (kN/M  2)  (W/kg) 
C57  250 -+ 29  60 -  18 
AabdlF (5)  182 ±  15  42 +  6 
mdx (6)  108 -  22  20 -+ 6 
*The  number of animals tested is given in parentheses following the name of the 
mouse line. 
CData are expressed as the mean followed by the value for one standard error of the 
mean. 
transgenic mdx mice was 30% less than control mice, com- 
pared with a  64%  decrease for the mdx mice (Table II). 
These data demonstrate that the deleted protein is semi- 
functional, being able to prevent the appearance of much, 
but not all, of the pathological defects displayed by mdx mice. 
Since  the  internally  truncated  dystrophin  appeared  to 
function close to normal in the absence of wild-type dys- 
trophin, we determined  if its expression would have any 
effect in  the  presence  of full-length  dystrophin.  Such  a 
dominant negative effect might be predicted for a protein 
that functions as a dimer, and would indicate whether the 
mutant protein could compete for binding sites or perhaps 
form unstable  or  nonfunctioning  dimers  able  to perturb 
the  normal function  of dystrophin.  To address this  issue 
we  performed  morphological  analysis  of transgenic  line 
Aabd-2F  after  crossing  it  onto  a  wild-type  background. 
However, no differences between transgenic or wild-type 
mice in either the percentage of myofibers with centrally 
looated nuclei or the morphological state of the quadriceps 
or diaphragm muscles were observed (data not shown). 
Sarcomeric Localization of the Truncated Dystrophin 
A  number of reports have localized dystrophin to the sar- 
colemma in a punctate pattern at both M  and Z-line cos- 
tameres (Straub et al., 1992; Porter et al., 1992; Masuda et al., 
1992).  In addition, Masuda et al. (1992) observed regular 
internal cross striations in longitudinal sections of skeletal 
muscle  fibers  using  antibodies  specific  for  dystrophin. 
Straub  and  colleagues  (1992)  observed  similar  internal 
staining with dystrophin antibodies, but attributed the sig- 
nal  to a  cross reaction of their antibodies with e~-actinin. 
This localization may be due to interactions  between the 
NH2 terminus of dystrophin and elements of the cytoskel- 
eton. To determine whether the actin-binding domain de- 
letion in our transgenic mice would affect the myofibrillar 
localization of dystrophin, we examined longitudinally ori- 
ented quadriceps muscle sections using ultrathin cryosec- 
tions, which due to their decreased focal plane, allow for a 
much sharper image with greater resolution than normal 
thin sections. Our antibodies against the COOH-terminal 
Figure 5.  Histological  analysis of diaphragm  muscle. Haematoxy- 
lin and eosin  staining  of diaphragm muscle  strips  from control 
C57BL/10 (A), mdx (B), transgenic line Aabd-lF (C), and two ex- 
amples from transgenic line Aabd-2F (D and E). As in the quadri- 
ceps muscle  (Fig. 4),  the transgenic  mdx diaphragm from line 
Aabd-lF displays  little  fibrosis,  few necrotic fibers,  and only a 
slight increase  in centrally  nucleated fibers compared with con- 
trol muscle. Transgenic  line Aabd-2F, which is an independently 
derived line from line 1F, displayed variable expression by immu- 
nofluorescence.  Similarly, a variable pathology was observed in 
the diaphragm from animals of this line. Some regions displayed 
a  relatively  normal diaphragm  muscle  morphology (D),  while 
other regions displayed moderate to extensive dystrophy (E). Bar 
is 100 microns. 
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ogy with ct-actinin, but to ensure that these antibodies do 
not cross-react with other proteins in mdx mice, mdx quad- 
riceps  muscle  sections  were  tested  by  double  immuno- 
fluorescence labeling with  antibodies  against  dystrophin 
and a-actinin. The results indicated that the dystrophin an- 
tisera did not cross-react with a-actinin or other myofibrillar 
proteins (Fig. 6). Analysis of ultrathin sections in control 
mice revealed dystrophin staining  at  the  sarcolemma in 
discrete patches at both M- and Z-lines (arrowheads), and 
internally in the myofiber in a striated pattern correspond- 
ing to the Z-line (arrows), and, weakly, at the M-line (Fig. 
7 A). In the ultrathin sections of transgenic mdx skeletal 
muscles  a  similar  pattern  of staining  at  both  the  sarco- 
lemma and at the internal regions of the myofiber was ob- 
served (Fig.  7  B).  Hence, the  localization of dystrophin 
does not appear disturbed by a deletion in the actin-bind- 
ing  domain.  Confocal  microscopic  analysis  of  a  single 
teased  fiber  from  control  quadriceps  muscle  double 
stained with antisera against the dystrophin COOH termi- 
nus  and  a-actinin confirmed that the major intracellular 
dystrophin staining colocalized with ct-actinin at the Z-line 
(not shown). Similar staining is observed in control mice 
with  antibodies  we  raised  against  the  NH2-terminal do- 
main of dystrophin (not shown). These results confirm ear- 
lier reports of sarcomeric dystrophin localization that used 
NH2-terminal antibodies,  and show the same  results  are 
obtained with COOH-terminal antibodies that do not cross 
react with a-actinin (Masuda et al., 1992; Porter et al., 1992). 
Since the NHe-terminal domain of dystrophin binds ac- 
tin, we determined if the deletion had any effect on the lo- 
calization pattern of actin in skeletal muscle. In addition, 
the localization of dystrophin at costameres led to the hypo- 
thesis that dystrophin is associated with other components 
of the cytoskeleton. Therefore, the localization patterns of 
actin  and  of the  costamere-associated  protein  c~-actinin 
were determined. Filamentous actin localization was simi- 
lar in both control mice and in the transgenic mdx mice, as 
Figure 6.  Analysis of dystrophin antisera on rndx mouse muscle. 
Ultrathin cryosections from rndx mouse quadriceps were immuno- 
stained with (a) affinity-purified COOH-terminal dystrophin an- 
tisera or (b) antisera against ct-actinin. No cross reactivity with 
a-actinin or other cytoskeletal proteins was  observed either on 
these thin sections or by Western analysis (Cox et al.,  1994). A 
positively staining region from a  'revertant' mdx myofiber in a is 
visible. Bar is 10 microns. 
judged by phalloidin staining (Fig. 7, C and D). In both the 
control and transgenic mdx mice e~-actinin staining was ob- 
served in a striated pattern at the Z-lines, in a pattern sim- 
ilar  to  that  observed  for dystrophin  (Fig.  7,  E  and  1). 
Hence, at the light microscopy level, transgenic mdx skeletal 
muscle does not display any perturbation of the localiza- 
tion of dystrophin or these other two cytoskeletal proteins. 
Discussion 
Correlation between the molecular nature of mutations at 
the DMD locus and clinical phenotypes has provided con- 
siderable  insight  into  the  importance  of different func- 
tional  domains  of  dystrophin.  Several  groups  have  ob- 
served  that  in-frame  deletions  in  domain  I  result  in  a 
greater phenotypic variability with a clinical course that is 
more severe than expected for typical BMD patients (Mal- 
holtra et al.,  1988; Baumbach et al.,  1989;  Koenig et al., 
1989; Beggs et al.,  1991; Comi et al., 1994; Muntoni et al., 
1994). Beggs and colleagues (1991) observed that patients 
with domain I deletions typically had low levels of dystro- 
phin, relatively early onset of symptoms, and severe pro- 
gression of muscle degradation.  Muntoni and colleagues 
(1994)  reported  that  patients  with  in-frame  deletions 
within domain f display a less intense pattern of immuno- 
histochemical staining and a faster progression of skeletal 
muscle degeneration compared with patients affected by de- 
letions in  the central rod domain.  These results  suggest 
that domain I is important for the normal function of dys- 
trophin.  Alternatively, the very low levels of dystrophin 
observed in patients with domain I deletions could suggest 
that the more severe than expected phenotypes result pri- 
marily from decreased expression of a fully functional pro- 
tein. 
Mice that expressed the truncated protein at or above 
normal levels manifested relatively few of the pathological 
abnormalities  found in mdx  mouse quadriceps  and  dia- 
phragm muscles. The diaphragms of these mice generated 
levels of force and power closer to those observed in con- 
trol than in rndx mice (Table II). In addition, no obvious 
alterations were observed in the localization of dystrophin, 
actin, or c~-actinin between the transgenic and control mice. 
These results indicate that normal expression of a dystro- 
phin  protein with  a  deletion in  domain  I  leads  to what 
might be termed a "mild Becker" phenotype in mdx mice. 
Interestingly, none of the twelve lines of transgenic mice 
we generated expressed the transgene at the high levels 
(5-50  times  normal)  we  observed  for  other  dystrophin 
constructs that used similar gene regulatory elements (Cox 
et al., 1993; Rafael et al., 1994; Phelps et al., 1995). Human 
patients with in-frame deletions in domain I  also express 
very low levels of the truncated proteins. Consequently, 
this inability to obtain high level expression in mice may 
be due to an instability of the protein due to an improper 
folding or to weakened linkages with the cytoskeleton. Ei- 
ther condition might cause the protein to be more accessi- 
ble to protease digestion. 
Development of such a mild phenotype in mice after de- 
letion of the vast majority of the dystrophin actin-binding 
domain is surprising, particularly since deletion of the cys- 
teine-rich COOH-terminal DGC-binding site leads to the 
development of a  severe dystrophy in  humans  and  mice 
The Journal of Cell Biology, Volume 134, 1996  880 Figure 7. Immunofluorescence analysis using ultrathin cryosections. Longitudinally  oriented 0.5 micron cryosections of quadriceps mus- 
cle from control (A, C, and E) and transgenic mdx mice (B, D, and F) were stained with anti-dystrophin antibodies (A and B), phalloidin 
(C and D) or anti-~-actinin antibodies (E and F). Dystrophin staining was observed at the sarcolemma in discrete patches at both M- and 
Z-lines (arrowheads),  and internally in the myofiber in a striated pattern corresponding to the I band (arrows), and, weakly, at the M-line. 
No differences were noted between the localization of dystrophin, ct-actinin, or actin between control and transgenic-mdx animals. Bar 
is 10 microns. 
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of dystrophin function suggest any mutation that leads to a 
disruption of the linkage between the subsarcolemmal cy- 
toskeleton and the extracellular matrix should be associ- 
ated with a severe dystrophy (Campbell, 1995).  Since our 
transgenic mice display a relatively mild phenotype, and 
since some patients with 5' gene deletions develop BMD 
rather than DMD, it seems likely that dystrophin can at- 
tach to the subsarcolemmal cytoskeleton in a more com- 
plex manner  than  has  generally been  assumed.  Several 
mechanistic  interpretations  seem  reasonable  to  explain 
these observations. Dystrophin may contain multiple actin- 
binding sites, such that deletion of one site would enable 
actin binding by a remaining site or sites. These multiple 
actin-binding sites could normally function simultaneously 
in a  dystrophin protein. Alternatively, deletion of a  pri- 
mary actin-binding domain could lead to conformational 
changes that unmask cryptic binding sites not efficiently 
used in an intact protein. Another possibility is that dys- 
trophin can bind to multiple components of the actin cy- 
toskeleton, such that disruption of a link with actin might 
not  seriously affect a  direct connection with other pro- 
teins, such as talin, aciculin, or calmodulin. 
Analysis of multiple patients with deletions in domain I 
has suggested that exon 3 and exon 5 are important for 
dystrophin function (Muntoni et al., 1994). We and others 
have shown that the actin-binding domain of dystrophin 
contains at least three sites of interaction between actin 
and  dystrophin:  ABS1  (amino  acids  18-27,  in  exon  2), 
ABS2 (amino acids 131-148, in exon 6), and ABS3 (amino 
acids 91-117,  in exon 5)  (Levine et al.,  1990,  1992; Fab- 
brizio et al., 1993; Corrado et al., 1994; Jarrett and Foster, 
1995).  The deletion construct used in this study extends 
from the middle of exon 3 to the middle of exon 8 and thus 
joins amino  acid 44  to the middle  of hinge  1, removing 
ABS2  and  ABS3  but  retaining  ABS1.  It has  been  sug- 
gested that ABS2 and ABS3 are more critical to dystro- 
phin function than is ABS1. Jarrett and Foster (1995) have 
shown that the binding of ABS 2  and 3 to actin is  of a 
much greater affinity than the binding of ABS1  alone to 
actin. The majority of patients with in-frame domain I de- 
letions that retain ABS1 display a severe BMD phenotype 
(Beggs et al., 1992; Comi et al., 1994; Muntoni et al., 1994). 
These studies and our results suggest an intact domain I is 
not essential for function and that the severe phenotype 
seen in these patients is due to the lower levels of dystro- 
phin. We cannot rule out the possibility that the truncated 
protein in our transgenic mice is binding weakly to actin at 
ABS1 or at other unidentified sites. 
Additional unidentified protein-binding sites could exist 
in the dystrophin NH2 terminus, which might facilitate for- 
mation of a broad multi-component linkage with the sub- 
sarcolemmal  cytoskeleton. The only detectable form  of 
dystrophin in some BMD patients with an exon 3-7 dele- 
tion is generated by translation initiation in exon 8 (Win- 
nard et al.,  1995), which suggests an interaction with the 
cytoskeleton distal  to exon 8.  Other  evidence indicates 
dystrophin can bind to additional cytoskeletal proteins, in- 
cluding  talin  (Senter  et  al.,  1993),  aciculin  (Belkin  and 
Burridge, 1995), and at the NH2 terminus to calmodulin 
(Bonet-Kerrache  et  al.,  1994;  Jarrett  and  Foster,  1995; 
Winder and  Kendrick-Jones, 1995).  Hori and colleagues 
(1995) have demonstrated that the NH2-terminal half of 
dystrophin is broadly protected from proteolysis in vivo, 
suggesting  that  a  large  region of the molecule interacts 
with  cytoskeletal  components.  Additional  observations, 
such as the demonstration that dystrophin is phosphory- 
lated in vitro by a variety of protein kinases, suggest that 
the NH2-terminal domain could also be involved in regu- 
lating the association of dystrophin with other cytoskeletal 
elements (Madhaven and Jarrett, 1994; Senter et al., 1995). 
Thus, phenotypic effects caused by deletions in the NH2- 
terminal domain could also be caused by an improper reg- 
ulation of dystrophin-cytoskeletal interactions rather than 
an inability to bind actin per se. Regardless of the precise 
mechanism by which NH2-terminal deletions lead to dys- 
trophy, our data indicate that increased accumulation of 
the deleted protein can lead to an amelioration of symp- 
toms. Attachment of dystrophin to the cytoskeleton via ac- 
tin  is  likely weakened  by such  deletions,  and  having  a 
larger pool of protein available for binding may help main- 
tain greater overall strength in the cytoskeletal-extracellu- 
lar matrix linkage. 
Since many severely affected BMD patients accumulate 
less dystrophin than more mildly affected patients, it has 
been suggested that improvement of a patient's phenotype 
might be attained if the level of dystrophin accumulation 
could be boosted (Beggs et al., 1991). The degree of phe- 
notypic improvement that could be attained would obvi- 
ously vary with the type of mutation present in a patient 
and whether critical functional domains are removed from 
the expressed protein. The unknown stability of truncated 
dystrophin proteins  resulting from various  deletion  and 
splicing mutations has complicated interpretation of the 
effect of those mutations on various dystrophin functional 
domains (Roberts et  al.,  1994;  Amalfitano et al.,  1996). 
Our study indicates that moderate functional deficits re- 
sulting from deletions in the NH/-terminal domain of dys- 
trophin are exacerbated by low level expression of the rel- 
atively unstable,  truncated  protein.  Hence,  although  an 
intact actin-binding domain may not be essential, it does 
contribute  to  an  important  function of dystrophin.  The 
deleterious effect of loss of this function can be lessened 
significantly by overproduction of the truncated protein. 
This result is in marked contrast to deletions of the central 
rod domain, and to many in the COOH-terminal domain 
of dystrophin. We and others have demonstrated in trans- 
genic mice that  deletion of portions of the rod domain 
generate proteins that are almost fully functional even at 
levels only 20% of the control value (Phelps et al.,  1995; 
Wells et al., 1995), whereas deletion of the cysteine-rich 
domain leads to a  severe phenotype, even when control 
levels of the protein are  expressed (Rafael  et al,  1996). 
Continued  efforts to develop detailed  structure/function 
models for dystrophin using  data from patients need to 
consider the effect of a particular deletion on the accumu- 
lation of the truncated dystrophin. 
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Note Added in Proof, Recent data suggests that dystrophin may bind actin 
filaments  via  multiple  sites  throughout  the  NH2-terminal  and  rod  do- 
mains, which could explain the mild phenotype in our transgenic animals 
(James Ervasti, personal communication). 
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